RecallRadar

FDA Drug recall D-1095-2014

Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0…

On 2014-03-12 the FDA classified a Class II recall of Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0… by Teva Pharmaceuticals Usa, citing CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1095-2014
ClassificationClass II
Statusterminated
Initiated2014-01-24
Published2014-03-12
Last updated2026-09-13 11:51 UTC
CompanyTeva Pharmaceuticals Usa
DistributionUS

Product

Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0555-0323-02.

Reason

CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Identifiers

ndc0555-0323-02
ndc0555-0323-04
ndc0555-0302-02
ndc0555-0302-04
ndc0555-0324-02
code_infoLot # 34016752A, Exp. 09/16. Lot # 34016753A, Exp. 09/16.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1095-2014%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.